Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : HuMAB companies -- Ignore unavailable to you. Want to Upgrade?

To: nigel bates who wrote (44)	9/6/2000 12:03:46 PM
From: JOEBT1	Read Replies (2) \| Respond to of 1022

Nigel--IMGN is a bonafide technology platform biotech company based on their tumor activated pro drug. This is their third deal-ABGX, DNA and British Biotech. They will probably announce 1 to 2 more deals this year. Their Phase I/II trial on colon and pancreatic cancer is going very well. They are into the 10th month and are giving their 7th escalating dose to find the MTD with no immunogenicity and side effects so far (Harmon, please note). All patients are refractory and continue in the trial only if disease is not progressing. The multidose P I/II trial is about to start with SB in the lead. Selling on the news today but the best is yet to come.

To: nigel bates who wrote (44)	9/6/2000 2:58:28 PM
From: aknahow	Respond to of 1022

How XOMA views it's HUMab technology. Not endorsing this view just posting for any that might be interested or for any that want to discuss it or diss it. Human Engineering What advantages does XOMA's Human Engineering technology have over technologies such as transgenic mouse antibodies? There are several distinct ways to prepare therapeutic antibodies with low immunogenicity potential in humans. The XOMA Human Engineering technology enables production of clinically useful antibodies from pre-existing mammalian monoclonal antibodies, in contrast to transgenic mouse technology, which generates antibodies de novo to existing targets. The effectiveness of any particular method of generating an antibody with reduced immunogenicity will ultimately need to be proved for each product in clinical trials. Nevertheless, advantages of XOMA's HE method may include the following: 1. Simplicity. HE is a straightforward method for antibody modification that can be directed by a computerized spreadsheet. This method can be applied to ANY antibody sequence without additional experimentation. 2. Versatility. HE can improve the usefulness of the large number of existing, well-characterized murine monoclonal antibodies to human antigens that are already available. No new immunizations or selections are required to create new "human" antibodies in mice for these already identified targets. 3. Reliability. HE doesn't depend on the immune systems of transgenic mice for the end product. Human Engineered™ antibodies retain the binding characteristics of the 'parent' antibody 4. Speed: HE antibody genes can be generated in a few days. Mammalian cell lines that express HE antibodies can be generated in approximately 3 months. 5. Economy: The HE method is easy to use, leading to potential cost savings. There are no animals to maintain and only one royalty to pay. If the XOMA HE technology is a novel approach why hasn't it been licensed yet? There is a large installed base of other licensed technology, and ours is a recent entry. We are planning to initiate clinical studies in the next year with two HE products, ING-1 and Genimune. These studies will provide data about how human subjects respond to these compounds.